Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 401–500 of 1,002
The role of the symbiotic microecosystem in cancer: gut microbiota, metabolome, and host immunome
Xue, X., Li, R., Chen, Z., Li, G., Liu, B., Guo, S., Yue, Q., Yang, S., Xie, L., Zhang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235827 · Cited by 39
Liu, Y., Altreuter, J., Bodapati, S., Cristea, S., Wong, C. J., Wu, C. J., & Michor, F. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100444 · Cited by 48
Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer
Li, Y., Chang, R. B., Stone, M. L., Delman, D., Markowitz, K., Xue, Y., Coho, H., Herrera, V. M., Li, J. H., Zhang, L., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101397 · Cited by 45
Optimizing Cancer Treatment Through Gut Microbiome Modulation
Kim, K., Lee, M., Shin, Y., Lee, Y., & Kim, T. J. (2025) · Cancers · doi:10.3390/cancers17071252 · Cited by 38
The Effect of Microbiome-Derived Metabolites in Inflammation-Related Cancer Prevention and Treatment
Mafe, A. N., & Büsselberg, D. (2025) · Biomolecules · doi:10.3390/biom15050688 · Cited by 42
Greathouse, K. L., & Choudhury, A. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.05.011 · Cited by 41
Lu, Y., Yuan, H., Liang, S., Li, D., Jiang, P., Wang, X., Zhang, K., & Liu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603658 · Cited by 45
Sumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 36
The Application of High-Throughput Technologies for the Study of Microbiome and Cancer
Wei, L., Cheong, I. H., Yang, G., Li, X. G., Kozlakidis, Z., Ding, L., Liu, N. N., & Wang, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.699793 · Cited by 43
The Effect of Radiation and Chemoradiation Therapy on the Head and Neck Mucosal Microbiome: A Review
Zagury‐Orly, I., Khaouam, N., Noujaim, J. C., Desrosiers, M. Y., & Maniakas, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.784457 · Cited by 38
Tonneau, M., Nolin-Lapalme, A., Kazandjian, S., Auclin, E., Panasci, J., Benlaifaoui, M., Ponce, M., Al-Saleh, A., Belkaid, W., Naimi, S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2096535 · Cited by 34
Microbiota-directed biotherapeutics: considerations for quality and functional assessment
Fekete, E. E. F., Figeys, D., & Zhang, X. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2186671 · Cited by 38
Mullish, B. H., Merrick, B., Quraishi, M. N., Bak, A., Green, C., Moore, D., Porter, R. J., Elumogo, N., Segal, J. P., Sharma, N., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331550 · Cited by 43
The link among microbiota, epigenetics, and disease development
El-Sayed, A., Aleya, L., & Kamel, M. S. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-13862-1 · Cited by 38
Current status and future perspective of immune checkpoint inhibitors in colorectal cancer
Zhou, C., Cheng, X., & Tu, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.023 · Cited by 37
Giuliano, A. (2021) · Biology · doi:10.3390/biology11010054 · Cited by 47
Tao, Y., Zhu, F., Pan, M., Liu, Q., & Wang, P. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.857370 · Cited by 46
Translating Microbiome Research From and To the Clinic
Zhang, Z. J., Lehmann, C. J., Cole, C. G., & Pamer, E. G. (2022) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041020-022206 · Cited by 33
Microbiome influencers of checkpoint blockade–associated toxicity
Wang, Y., Jenq, R. R., Wargo, J. A., & Watowich, S. S. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220948 · Cited by 37
Self-citationImmunological consequences of microbiome-based therapeutics
Alam, M. Z., Maslanka, J. R., & Abt, M. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1046472 · Cited by 43
Advances in targeted therapy and immunotherapy for melanoma (Review)
Qin, Z., & Zheng, M. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12115 · Cited by 37
MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody
Lee, P.-J., Hung, C.-M., Yang, A.-J., Hou, C.-Y., Chou, H.-W., Chang, Y.-C., Chu, W.-C., Huang, W.-Y., Kuo, W.-C., Yang, C.-C., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2380061 · Cited by 33
“…two studies reported that the clinical response rates were 30% (3 of 10) and 20% (3 of 15) in patients with refractory melanoma who were reintroduced to anti-PD1 therapy, 13,14 which were higher than that in patients who were retreated with anti-PD1 therapy alone (5 out of 34, 14.7%).”
BackgroundInfluentialSepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Pederzoli, F., Riba, M., Venegoni, C., Marandino, L., Bandini, M., Alchera, E., Locatelli, I., Raggi, D., Giannatempo, P., Provero, P., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.12.014 · Cited by 33
Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease
Thomas, A. S., Hanauer, S. B., & Wang, Y. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.10.004 · Cited by 38
Zhuang, Y.-P., Zhou, H., Chen, H., Zheng, M.-Y., Liang, Y., Gu, Y.-T., Li, W., Qiu, W., & Zhou, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115040 · Cited by 37
Chen, Q., Zhu, Y., Wang, K., Wang, X., Zhang, Y., Zhou, M., Du, J., Qu, X., Shi, Z., Zhang, Y., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101994 · Cited by 38
Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic
Ríos-Hoyo, A., & Arriola, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221097 · Cited by 35
Jiang, H., & Zhang, Q. (2024) · Oncology Letters · doi:10.3892/ol.2024.14221 · Cited by 36
Allegretti, J. R., Khanna, S., Mullish, B. H., & Feuerstadt, P. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.004 · Cited by 37
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
Zhang, M., Bzura, A., Baitei, E. Y., Zhou, Z., Spicer, J., Poile, C., Rogel, J., Branson, A., King, A., Barber, S. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49842-5 · Cited by 38
Bacterial live therapeutics for human diseases
Frutos-Grilo, E., Ana, Y., Miguel, J. G.-D., Cardona-I-Collado, M., Rodríguez-Arce, I., & Serrano, L. (2024) · Molecular Systems Biology · doi:10.1038/s44320-024-00067-0 · Cited by 38
Luo, B., Zhang, Y., Zhang, C., Liu, X., & Shi, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.001 · Cited by 34
Ninkov, M., Schmerk, C. L., Moradizadeh, M., Parvathy, S. N., Figueredo, R., Burton, J. P., Silverman, M. S., Fernandes, R., Maleki Vareki, S., & Haeryfar, S. M. M. (2023) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03329-8 · Cited by 32
Wang, Q., Shen, X., Chen, G., & Du, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34464 · Cited by 38
Checkpoint inhibitor responses can be regulated by the gut microbiota – A systematic review
Zeriouh, M., Raskov, H., Kvich, L., Gögenür, I., & Bennedsen, A. L. B. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100923 · Cited by 33
Exploiting the gut microbiome for brain tumour treatment
Keane, L., Cryan, J. F., & Gleeson, J. P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.08.008 · Cited by 33
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
Self-citationRoles of Microbiota in Cancer: From Tumor Development to Treatment
Bagheri, Z., Moeinzadeh, L., & Razmkhah, M. (2022) · Journal of Oncology · doi:10.1155/2022/3845104 · Cited by 35
Wan, L., Wu, C., Wu, Q. J., Luo, S., Liu, J., & Xie, X. (2022) · Cancer Medicine · doi:10.1002/cam4.4994 · Cited by 33
Wang, L., Chen, J., Chen, Q., Song, H., Wang, Z., Wen, X., Jin, S., Song, X., Yang, H., & Zhao, W. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/6480848 · Cited by 36
Decoding the microbiome: advances in genetic manipulation for gut bacteria
Chen, Z., Jin, W., Hoover, A., Chao, Y., & Ma, Y. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.05.007 · Cited by 32
Queen, J., Shaikh, F. Y., & Sears, C. L. (2023) · Nature Cancer · doi:10.1038/s43018-023-00602-2 · Cited by 36
Jamal, R., Messaoudene, M., de Figuieredo, M., & Routy, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101754 · Cited by 31
Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma
Shen, S., Khatiwada, S., Behary, J., Kim, R., & Zekry, A. (2022) · Cancers · doi:10.3390/cancers14092099 · Cited by 34
Emerging roles of the gut microbiota in cancer immunotherapy
Shi, Z., Li, H., Song, W., Zhou, Z., Li, Z., & Zhang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139821 · Cited by 34
The bacterial microbiome and cancer: development, diagnosis, treatment, and future directions
Qasem, H., & El-Sayed, W. M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01523-9 · Cited by 34
Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors
Awosika, J. A., Gulley, J. L., & Pastor, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094394 · Cited by 42
Intestinal dysbiosis and colorectal cancer
Kang, Z., Jiang, S., Fang, J., & Chen, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003617 · Cited by 38
Microbiota-induced T cell plasticity enables immune-mediated tumour control
Najar, T. A., Hao, Y., Hao, Y., Romero‐Meza, G., Dolynuk, A., Almo, E., & Littman, D. R. (2026) · Nature · doi:10.1038/s41586-025-09913-z · Cited by 39
Exploiting the obesity-associated immune microenvironment for cancer therapeutics
Desharnais, L., Walsh, L. A., & Quail, D. F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107923 · Cited by 31
Bird, B., Nally, K., Ronan, K. E., Clarke, G. A., Amu, S., Almeida, A. S., Flavin, R., & Finn, S. P. (2022) · Diagnostics · doi:10.3390/diagnostics12010124 · Cited by 31
Gut microbiota shed new light on the management of immune‐related adverse events
Tan, B., Liu, Y., Tang, H. T., Chen, D., Xu, Y., Chen, M., Li, Y., Wang, M., & Qian, J. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14626 · Cited by 36
The role of the sex hormone-gut microbiome axis in tumor immunotherapy
Wang, L., Tang, L., Zhai, D., Song, M., Li, W., Xu, S., Jiang, S., Meng, H., Liang, J., Wang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185035 · Cited by 34
Shaikh, F. Y., Gills, J. J., Mohammad, F., White, J. R., Stevens, C. M., Ding, H., Fu, J., Tam, A., Blosser, R. L., Domingue, J. C., et al. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03169-6 · Cited by 30
“In fact, recent data from two pilot clinical trials suggest that fecal microbiota transfer (FMT) from patients with responsive tumors to anti-PD-1 nonresponsive patients with melanoma may enhance the anti-tumor response to ICIs in some cases [10, 11].”
BackgroundMicrobiota as the unifying factor behind the hallmarks of cancer
Benešová, I., Křížová, Ľ., & Kverka, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05244-6 · Cited by 35
Influence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome
Ghani, R., Chrysostomou, D., Roberts, L. A., Pandiaraja, M., Marchesi, J. R., & Mullish, B. H. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2423026 · Cited by 33
Zhang, M., Wei, Z., Wei, B., Lai, C., Zong, G., Tao, E., Fan, M., Pan, Y., Zhou, B., Shen, L., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.022 · Cited by 35
Kong, X., Lü, P., Liu, C., Guo, Y., Yang, Y., Peng, Y., Wang, F., Zhang, B., Dou, X., Shi, H., et al. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12001 · Cited by 30
Establishment and Resilience of Transplanted Gut Microbiota in Aged Mice
Wang, Y., Tang, J., Lv, Q., Tan, Y., Dong, X., Liu, H., Zhao, N., He, Z., Kou, Y., Tan, Y. Q., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103654 · Cited by 39
The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
Modica, M. D., Arlotta, V., Sfondrini, L., Tagliabue, E., & Triulzi, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947188 · Cited by 36
Liu, X., Tang, H. T., Zhou, Q., Zeng, Y., Lu, B., Chen, D., Li, Y., Qian, J., Chen, M., Zhao, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109281 · Cited by 35
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma
Yavuz, B. G., Datar, S. S., Chamseddine, S., Mohamed, Y. I., LaPelusa, M. B., Lee, S. S., Hu, Z. I., Koay, E. J., Cao, H. S. T., Jalal, P. K., et al. (2023) · Cancers · doi:10.3390/cancers15194875 · Cited by 34
DeFilipp, Z. M., Damania, A. V., Kim, H. T., Chang, C., El-Jawahri, A. R., McAfee, S. L., Bottoms, A. S., Toncheva, V., Smith, M. M., Dolaher, M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012556 · Cited by 33
Self-citationFarias, R. M., Jiang, Y., Levy, E. J., Hwang, C. H., Wang, J., Burton, E. M., Cohen, L. G., Ajami, N., Wargo, J. A., Daniel, C. R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13234-1 · Cited by 42
Self-citationZhang, C., Wang, Y., Cheng, L., Cao, X., & Liu, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1557959 · Cited by 42
A review of engraftment assessments following fecal microbiota transplant
Herman, C., Barker, B. M., Bartelli, T. F., Chandra, V., Krajmalnik‐Brown, R., Jewell, M., Li, L., Liao, C., McAllister, F. M., Nirmalkar, K., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2525478 · Cited by 36
Advances and challenges in the treatment of osteosarcoma
Wang, X., Zhu, K., Hu, J., & Zhang, C. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.07.001 · Cited by 36
Sakurai, T., Velasco, M. A. D., Sakai, K., Nagai, T., Nishiyama, H., Hashimoto, K., Uemura, H., Kawakami, H., Nakagawa, K., Ogata, H., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13062 · Cited by 30
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 31
Thompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09156-x · Cited by 32
Brevi, A., Cogrossi, L. L., Lorenzoni, M., Mattorre, B., & Bellone, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845422 · Cited by 32
Zheng, M., Zhou, W., Huang, C., Hu, Z. Q., Zhang, B., Lu, Q., & Zhao, M. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102989 · Cited by 29
Zareie, P., Weiss, E. S., Kaplan, D. H., & Mackay, L. K. (2025) · Nature Immunology · doi:10.1038/s41590-025-02145-3 · Cited by 29
Xie, N.-N., Wu, C., Ge, Q., Zhou, J., Long, F., Mao, Q., Li, S., & Shen, H. (2022) · Food & Function · doi:10.1039/d2fo03383f · Cited by 30
Haberman, Y., Kamer, I., Amir, A., Goldenberg, S., Efroni, G., Daniel‐Meshulam, I., Lobachov, A., Daher, S., Hadar, R., Gantz-Sorotsky, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29136-4 · Cited by 33
Gut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
Zhang, H., & Xu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1257515 · Cited by 33
Microbiome in Cancer Development and Treatment
Čierniková, S., Ševčíková, A., Mladosievičová, B., & Mego, M. (2023) · Microorganisms · doi:10.3390/microorganisms12010024 · Cited by 32
Zhang, P.-F., & Xie, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362133 · Cited by 39
The Roles of the Virome in Cancer
Broecker, F., & Moelling, K. (2021) · Microorganisms · doi:10.3390/microorganisms9122538 · Cited by 34
Hersi, F., Elgendy, S. M., Shamma, S. A. A., Altell, R. T., Sadiek, O., & Omar, H. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120573 · Cited by 31
Local Breast Microbiota: A “New” Player on the Block
Vitorino, M. M., Costa, D. A., Vicente, R. S., Caleça, T., & Santos, C. (2022) · Cancers · doi:10.3390/cancers14153811 · Cited by 30
Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition
Chen, W., Ma, Y., Wang, F., Liao, Y., Chen, Y., Zhao, B., Zhao, Q., Wang, D., & Tang, D. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221120708 · Cited by 33
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
“Furthermore, fecal microbiota transplantation (FMT) from ICI responders has shown potential to restore gut microbial balance and enhance therapeutic ef fi cacy 131 – 133 .”
The Species of Gut Bacteria Associated with Antitumor Immunity in Cancer Therapy
Qi, X., Liu, Y., Hussein, S., Choi, G., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Cells · doi:10.3390/cells11223684 · Cited by 30
Hwang, S. W., Kim, M. K., & Kweon, M. (2023) · Intestinal Research · doi:10.5217/ir.2023.00019 · Cited by 29
Crouch, L. I., Rodrigues, C. S., Bakshani, C. R., Tavares-Gomes, L., Gaifem, J., & Pinho, S. S. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101891 · Cited by 31
Tang, Y., Cai, Q., Tian, Z., Chen, W., & Tang, H. (2025) · Research · doi:10.34133/research.0600 · Cited by 35
Mannose Enhances Immunotherapy Efficacy in Ovarian Cancer by Modulating Gut Microbial Metabolites
Zhang, C., Wang, Y., He, M., Wang, C., Cao, K., Zhong, Y., Wang, X., Yang, M., Zhang, G., Lu, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3209 · Cited by 37
Labadie, B. W., Balar, A. V., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13215415 · Cited by 37
Using the microbiome in clinical practice
Turjeman, S., & Koren, O. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13971 · Cited by 26
Self-citationRedrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33
Microbial mechanisms to improve immune checkpoint blockade responsiveness
Griffin, M. E., & Hang, H. C. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100818 · Cited by 31
Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 29
Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy
Zhou, P., Hu, Y., Wang, X., Shen, L., Liao, X., Zhu, Y., Yu, J., Zhao, F., Zhou, Y., Shen, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877939 · Cited by 31
Regulation of T cell repertoires by commensal microbiota
Kim, K. S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1004339 · Cited by 36
Understanding and harnessing triple-negative breast cancer-related microbiota in oncology
Devoy, C., Bueso, Y. F., & Tangney, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020121 · Cited by 33
Zhu, X., Li, H., Zhou, L., Jiang, H., Ji, M., & Chen, J. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121250 · Cited by 28
The Human Gut Virome and Its Relationship with Nontransmissible Chronic Diseases
Ezzatpour, S., Mondragón, A. D. C., Cardelle‐Cobas, A., Lamas, A., López-Santamarina, A., Miranda, J. M., & Aguilar, H. C. (2023) · Nutrients · doi:10.3390/nu15040977 · Cited by 33
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.